1 month Corvus Pharmaceuticals (NASDAQ:CRVS) Lifted to “Hold” at StockNews.comMarketBeat
StockNews.com raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday.
Nasdaq 100 · Pharmaceuticals · Science
X